BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

810 related articles for article (PubMed ID: 25752441)

  • 1. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
    Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
    J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
    Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
    Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infiltration of CD3⁺ and CD68⁺ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors.
    Sjödahl G; Lövgren K; Lauss M; Chebil G; Patschan O; Gudjonsson S; Månsson W; Fernö M; Leandersson K; Lindgren D; Liedberg F; Höglund M
    Urol Oncol; 2014 Aug; 32(6):791-7. PubMed ID: 24794251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma.
    Koh J; Kim S; Kim MY; Go H; Jeon YK; Chung DH
    Oncotarget; 2017 Feb; 8(8):13762-13769. PubMed ID: 28099920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic relevance of preoperative circulating CD8-positive lymphocytes in the urinary bladder recurrence of urothelial carcinoma.
    Lin CT; Tung CL; Tsai YS; Shen CH; Jou YC; Yu MT; Wu SF
    Urol Oncol; 2012 Sep; 30(5):680-7. PubMed ID: 21420334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer.
    Liu K; Zhao K; Wang L; Sun E
    Pathol Res Pract; 2018 Aug; 214(8):1074-1080. PubMed ID: 29803657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High CD4⁺ T cell density is associated with poor prognosis in patients with non-muscle-invasive bladder cancer.
    Zhang Q; Hao C; Cheng G; Wang L; Wang X; Li C; Qiu J; Ding K
    Int J Clin Exp Pathol; 2015; 8(9):11510-6. PubMed ID: 26617883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of lymphocytes of the alpha(E)beta(7) phenotype and E-cadherin in normal human urothelium and bladder carcinomas.
    Cresswell J; Robertson H; Neal DE; Griffiths TR; Kirby JA
    Clin Exp Immunol; 2001 Dec; 126(3):397-402. PubMed ID: 11737053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma.
    Mann JE; Smith JD; Birkeland AC; Bellile E; Swiecicki P; Mierzwa M; Chinn SB; Shuman AG; Malloy KM; Casper KA; McLean SA; Moyer JS; Wolf GT; Bradford CR; Prince ME; Carey TE; McHugh JB; Spector ME; Brenner JC
    Cancer Immunol Immunother; 2019 Feb; 68(2):213-220. PubMed ID: 30361882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
    Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
    Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
    Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
    Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of CD103
    Han L; Gao QL; Zhou XM; Shi C; Chen GY; Song YP; Yao YJ; Zhao YM; Wen XY; Liu SL; Qi YM; Gao YF
    Cancer Immunol Immunother; 2020 Aug; 69(8):1493-1504. PubMed ID: 32285170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
    Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
    Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer.
    Horn T; Laus J; Seitz AK; Maurer T; Schmid SC; Wolf P; Haller B; Winkler M; Retz M; Nawroth R; Gschwend JE; Kübler HR; Slotta-Huspenina J
    World J Urol; 2016 Feb; 34(2):181-7. PubMed ID: 26055646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.
    Webb JR; Milne K; Nelson BH
    Cancer Immunol Res; 2015 Aug; 3(8):926-35. PubMed ID: 25957117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma.
    Ke HL; Chang LL; Yang SF; Lin HH; Li CC; Wu DC; Wu WJ
    Urol Oncol; 2011; 29(6):703-9. PubMed ID: 20022267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
    Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD103
    Wang P; Huang B; Gao Y; Yang J; Liang Z; Zhang N; Fu X; Li L
    Cell Immunol; 2018 Mar; 325():48-55. PubMed ID: 29448979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.